Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide Autogel in Congenital Hyperinsulinism
NCT01070758Phase 4Completed
- Sponsor
- Sheba Medical Center
- Start
- Feb 2010
- Primary completion
- Feb 2015
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 4 trial of lanreotide in congenital hyperinsulinism (HI), sponsored by Sheba Medical Center. Started Feb 2010; status: completed.
02
Drugs
lanreotide
03
Conditions
congenital hyperinsulinism (HI)
Beyond the preview
Go deeper on NCT01070758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01070758.